Published 13 days ago • loading... • Updated 13 days agoShow Less IconChardan Capital Initiates Coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) Summary by MarketBeatChardan Capital began coverage on MoonLake Immunotherapeutics in a research report on Friday. They issued a "buy" rating and a $57.00 price objective for the company.Share menu1 Articles1 ArticlesAllLeftCenter1RightSearch IconSort IconMarketBeatCenterFactualityOwnershipChardan Capital Initiates Coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX)Chardan Capital began coverage on MoonLake Immunotherapeutics in a research report on Friday. They issued a "buy" rating and a $57.00 price objective for the company.13 days ago·Sioux Falls, United StatesRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources1Leaning Left0Leaning Right0Center1Last Updated13 days agoBias Distribution100% CenterBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources are Center100% CenterC 100%Factuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageMarketBeat broke the news in Sioux Falls, United States 13 days ago on Friday, November 6, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsBaar Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsBaar Plus IconShow All